Advances in the study of ω-3 PUFA in heart failure / 中国临床药理学与治疗学

Free fatty acids, as important energy metabolism substrates for the heart, play an important role in various cardiovascular diseases; ω-3 PUFA, as an important branch of free fatty acids, has been confirmed by more and more researches to be closely related to cardiovascular diseases. Heart failure, as a common cardiovascular problem, seriously affects people's quality of life. Studies have shown that ω-3 PUFA plays a significant role in the development of heart failure. In this paper, we try to review the metabolism, pathogenesis and therapeutic significance of ω-3 PUFA in heart failure.

Continuous Renal Replacement Therapy: What Have We Learned And What Are Key Milestones For The Years To Come?

ABSTRACT Continuous renal replacement therapy (CRRT) is the main extracorporeal kidney support therapy used in critical ill patients in the intensive care unit (ICU). Since its conceptualization ~50 years ago, there have been major improvements in its technology and utilization. The last decade, and particularly since the COVID-19 pandemic, has been marked by a growing interest and demand of CRRT in worldwide ICUs. This has underpinned the need for improvements in nomenclature and process standardization, optimization of CRRT deliverables, and the development and validation of key performance indicators. Further, how to leverage digital health technologies to build clinical decision support for CRRT and improve personalized bedside decisions is a subject of intense investigation. Herein, we summarize notable advancements in the provision of CRRT and propose areas in need of further development.

Nuevos paradigmas en la hemofilia / New paradigms in hemophilia

Resumen La hemofilia es una diátesis hemorrágica producida por la deficiencia hereditaria de un factor (proteína) de la coagulación sanguínea que afecta principalmente a los varones. Su grado de severidad puede variar desde casos con poco sangrado, hasta condiciones muy graves que en muchas ocasiones llevan a la muerte a los enfermos. Existen dos tipos de hemofilia: la A por carencia del factor VIII y la B por falta del factor IX. En este editorial se resume de manera global la situación actual de los avances de la hemofilia desde el punto de vista clínico y del laboratorio.

Abstract Hemophilia is a hemorrhagic diathesis that is caused by the hereditary deficiency of a factor (protein) of blood clotting and that affects mainly men. Its degree of severity can vary from cases with little bleeding, to very serious conditions that often lead to death. There are two types of hemophilia, A for lack of factor VIII, and B for lack of factor IX. This editorial summarizes the current state of progress of hemophilia from the clinical and laboratory point of view.

POINT-OF-CARE ULTRASONOGRAPHY: NARRATIVE REVIEW

Point-of-care ultrasonography (POCUS) is a growing eld in medicine that allows clinicians to use ultrasonography at a patient's bedside, and it has transformed how clinicians deliver care. POCUS is used across various medical specialties, and non-radiologists and non-cardiologists can also become competent in the performance of POCUS, leading to increased adoption of this technology in clinical practice. POCUS and consultative ultrasonography are complementary, and both can be used together to provide a more comprehensive assessment of a patient's condition. In addition, POCUS is an invaluable tool that clinicians can use to monitor clinical conditions that can progress rapidly, such as acute respiratory failure, intracranial hypertension, and hemodynamic failure. Advances in POCUS technology have led to its use as a screening tool for the identication of certain disorders such as abdominal aortic aneurysm and for diagnosis of various medical conditions. POCUS has been associated with changes in clinical decision making in medical practice and has shown promising results in facilitating diagnosis and procedural guidance.

Análise de impacto orçamentário dos inibidores da PARP no tratamento do carcinoma de ovário avançado a partir de evidências de mundo real sob a perspectiva de um hospital federal referência em oncologia / Budget impact analysis of PARP inhibitors in the treatment of advanced ovarian cancer from on real-world evidence the perspective of a federal hospital reference in oncology

Objetivo: Avaliar o impacto orçamentário do tratamento com iPARP como primeira linha de manutenção, comparado ao tratamento-padrão a partir de evidências de mundo real sob a perspectiva de um hospital público referência em oncologia no Rio de Janeiro. Métodos: Foi aplicada uma análise de impacto orçamentário para estimar a introdução das tecnologias iPARP, olaparibe e niraparibe, em comparação com o cenário referência, utilizando dados de eficácia e evidências de mundo real, e considerando os custos globais de tratamento da doença em cinco anos. Este estudo foi aprovado pelo Comitê de Ética em Pesquisa, CAAE: 95157018.9.0000.5274. Resultados: A análise demonstrou que o cenário referência apresentou um impacto orçamentário no valor de R$ 3.578.768,04 em cinco anos. No cenário alternativo, o custo incremental do olaparibe chegou a ser 23,8% maior, comparado ao niraparibe, atingindo um custo de R$ 23.736.459,20 versus R$ 18.076.951,81, respectivamente. Os parâmetros que apresentaram maior impacto nas análises para a tecnologia olaparibe foram a difusão da tecnologia e o preço do medicamento. Contudo, para o niraparibe, os parâmetros de maior impacto foram a duração do tratamento, a difusão da tecnologia e a dose utilizada, demonstrando maior suscetibilidade de variação. Conclusão: Os iPARP no tratamento de pacientes com carcinoma de ovário avançado, apesar de apresentarem custo incremental de aproximadamente R$ 23 milhões em cinco anos, apontam para uma potencial redução de custos associados à progressão da doença.

Objective: Assess the budgetary impact of treatment with iPARP as a first line of maintenance, compared to standard treatment based on real-world evidence from the perspective of a public hospital reference in oncology at Rio de Janeiro. Methods: A budget impact analysis was applied to estimate the introduction of iPARP, olaparib and niraparib technologies, compared to the reference scenario, using efficacy data and real-world evidence, and considering the global costs of treating the disease in five years. This study was approved by the Research Ethics Committee, CAAE: 95157018.9.0000.5274. Results: The analysis showed that the reference scenario presented a budgetary impact of R$ 3,578,768.04 in five years. In the alternative scenario, the incremental cost of olaparib reached 23.8% higher compared to niraparib, reaching a cost of R$ 23,736,459.20 versus R$ 18,076,951.81, respectively. The parameters that had the greatest impact on the analyzes for the olaparib technology were technology diffusion and drug price. However, for niraparib, the parameters with the greatest impact were the duration of treatment, the diffusion of the technology and the dose used, demonstrating greater susceptibility to variation. Conclusion: iPARP in the treatment of patients with advanced ovarian carcinoma, despite having an incremental cost of approximately R$ 23 million in five years, point to a potential reduction in costs associated with disease progression.

Incorporação de esomeprazol em um hospital universitário: uma análise de custo-minimização / Incorporation of esomeprazole in a university hospital: a cost-minimization analysis

Introdução: Inibidores de bomba de prótons (IBP) são amplamente utilizados na profilaxia de úlceras de estresse. O omeprazol é o IBP mais prescrito no Brasil, porém, sua formulação oral convencional é inadequada para administração por sonda devido ao risco de obstrução. A apresentação injetável de omeprazol possui custo muito superior à formulação oral. O esomeprazol, por ser constituído de microgrânulos, é uma alternativa ao omeprazol injetável, pois pode ser administrado por sonda e ainda possibilitaria redução de custos. Objetivo: Analisar por meio de custo-minimização o impacto financeiro da incorporação do esomeprazol em um hospital universitário secundário. Material e Métodos: Estudo observacional transversal retrospectivo para identificar e analisar o consumo e custo relacionado ao uso de omeprazol injetável e esomeprazol nos anos de 2021 e 2022. A partir dos dados levantados, foi realizada análise de custo-minimização e determinado o impacto financeiro após incorporação do esomeprazol. Resultados: Houve redução de 76,7% no consumo de omeprazol injetável no ano de 2022. A análise de custo-minimização apontou um custo real de R$20.374,96 no ano de 2022, referente às 906 doses utilizadas no período, destas, 46,4% eram de omeprazol injetável e 53,6% de esomperazol. Considerando o cenário com terapia exclusiva com omeprazol injetável, o custo simulado foi de R$ 41.252,05. O impacto financeiro foi de R$ -20.877,09, resultando em economia de recursos de 50,6%. Conclusão: A incorporação de esomeprazol no elenco de medicamentos de um hospital universitário gerou redução significativa de custo, implicando em economia de mais de 50% no consumo global de IBP e de mais de 70% no consumo de omeprazol injetável, no ano de 2022.

Introduction: Proton pump inhibitors (PPIs) are widely used in stress ulcers prophylaxis. Omeprazole is the most prescribed PPI in Brazil, but its conventional oral formulation is unsuitable for administration through a tube due to the risk of obstruction. The injectable presentation of omeprazole has a much higher cost than the oral formulation. Esomeprazole, composed of microgranules, is an alternative to injectable omeprazole as it can be administered through a tube and could potentially lead to a cost reduction. Objective: To analyze, through cost minimization, the financial impact of incorporating esomeprazole in a secondary university hospital. Material and Methods: A retrospective cross-sectional observational study was conducted to identify and analyze the consumption and cost related to the use of injectable omeprazole and esomeprazole in the years 2021 and 2022. Cost-minimization analysis was performed based on the collected data, to determine the financial impact after incorporating esomeprazole. Results: There was a 76.7% reduction in the consumption of injectable omeprazole in 2022. The cost-minimization analysis indicated a real cost of R$20,374.96 in 2022 for the 906 doses used during the period, of which 46.4% were injectable omeprazole and 53.6% were esomeprazole. Considering the scenario with exclusive therapy using injectable omeprazole, the simulated cost was R$41,252.05. The financial impact was R$-20,877.09, resulting in a resource saving of 50.6%. Conclusion: The incorporation of esomeprazole into the list of medications at a university hospital led to a significant cost reduction, resulting in over 50% savings in PPI consumption and over 70% in injectable omeprazole consumption, in 2022.

A review of the recent advances on Lassa fever with special reference to molecular epidemiology and progress in vaccine development

Lassa fever, a viral hemorrhagic fever caused by the Lassa virus (LASV), is endemic in West Africa and is associated with high morbidity and mortality. At least three of the four proposed seven lineages of LASV are found in Nigeria, where the multimammate rat, Mastomys natalensis, serves as the primary reservoir. Endemic countries report approximately 200,000 infections and 5,000 deaths annually, with Nigeria experiencing thousands of infections and hundreds of deaths including healthcare workers. The aim of this review is to provide scientific information for better understanding of the evolutionary biology, molecular epidemiology, pathogenesis, diagnosis, and prevention of Lassa fever in Nigeria and other endemic regions worldwide, which can lead to improved control efforts and reduce morbidity and mortality from recurrent epidemics. To achieve this aim, observational studies such as case series, cross-sectional and cohort studies published between December 2017 and September 2022 were searched for on various online databases including Google Scholar, Africa Journals Online (AJOL), Research Gates, PubMed, PMIC, NCDC, and WHO websites. Although the origin and evolutionary history, and the transmission dynamics of Lassa virus have been revealed through recent. molecular epidemiological studies, the factors that drive the evolution of the virus remain unclear. Genetic changes in the viral genome may have enabled the virus to adapt to humans. Diagnosis of Lassa fever has also advanced from basic serological tests to more sophisticated methods such as quantitative real time polymerase chain reaction (qRT-PCR) and sequencing, which are particularly useful for identifying outbreak strains. Several vaccines, including recombinant vesicular stomatitis virus (rVSV), virus-like particle (VLP), and DNA-based vaccines, have shown promise in animal models and some have progressed to phase 2 clinical trials. Preventing and controlling Lassa fever is critical to safeguard the health and well-being of affected communities. Effective measures such as rodent control, improved sanitation, and early detection and isolation of infected individuals are essential for reducing transmission. Ongoing research into the genetic and ecological factors that drive the evolution of Lassa virus is necessary to reduce the impacts of Lassa fever.

A review of the recent advances on Lassa fever with special reference to molecular epidemiology and progress in vaccine development

Lassa fever, a viral hemorrhagic fever caused by the Lassa virus (LASV), is endemic in West Africa and is associated with high morbidity and mortality. At least three of the four proposed seven lineages of LASV are found in Nigeria, where the multimammate rat, Mastomys natalensis, serves as the primary reservoir. Endemic countries report approximately 200,000 infections and 5,000 deaths annually, with Nigeria experiencing thousands of infections and hundreds of deaths including healthcare workers. The aim of this review is to provide scientific information for better understanding of the evolutionary biology, molecular epidemiology, pathogenesis, diagnosis, and prevention of Lassa fever in Nigeria and other endemic regions worldwide, which can lead to improved control efforts and reduce morbidity and mortality from recurrent epidemics. To achieve this aim, observational studies such as case series, cross-sectional and cohort studies published between December 2017 and September 2022 were searched for on various online databases including Google Scholar, Africa Journals Online (AJOL), Research Gates, PubMed, PMIC, NCDC, and WHO websites. Although the origin and evolutionary history, and the transmission dynamics of Lassa virus have been revealed through recent molecular epidemiological studies, the factors that drive the evolution of the virus remain unclear. Genetic changes in the viral genome may have enabled the virus to adapt to humans. Diagnosis of Lassa fever has also advanced from basic serological tests to more sophisticated methods such as quantitative real time polymerase chain reaction (qRT-PCR) and sequencing, which are particularly useful for identifying outbreak strains. Several vaccines, including recombinant vesicular stomatitis virus (rVSV), virus-like particle (VLP), and DNA-based vaccines, have shown promise in animal models and some have progressed to phase 2 clinical trials. Preventing and controlling Lassa fever is critical to safeguard the health and well-being of affected communities. Effective measures such as rodent control, improved sanitation, and early detection and isolation of infected individuals are essential for reducing transmission. Ongoing research into the genetic and ecological factors that drive the evolution of Lassa virus is necessary to reduce the impacts of Lassa fever

La fièvre de Lassa, une fièvre hémorragique virale causée par le virus de Lassa (LASV), est endémique en Afrique de l'Ouest et est associée à une morbidité et une mortalité élevées. Au moins trois des quatre lignées proposées de LASV se trouvent au Nigeria, où le rat multimammaire, Mastomys natalensis, sert de réservoir principal. Les pays endémiques signalent environ 200,000 infections et 5,000 décès par an, le Nigéria connaissant des milliers d'infections et des centaines de décès, y compris des travailleurs de la santé. L'objectif de cette revue est de fournir des informations scientifiques pour une meilleure compréhension de la biologie évolutive, de l'épidémiologie moléculaire, de la pathogenèse, du diagnostic et de la prévention de la fièvre de Lassa au Nigeria et dans d'autres régions endémiques du monde, ce qui peut conduire à des efforts de contrôle améliorés et réduire la morbidité et la mortalité des épidémies récurrentes. Pour atteindre cet objectif, des études observationnelles telles que des séries de cas, des études transversales et de cohorte publiées entre décembre 2017 et septembre 2022 ont été recherchées sur diverses bases de données en ligne, notamment Google Scholar, Africa Journals Online (AJOL), Research Gate, PubMed, PMIC, Sites Web du NCDC et de l'OMS. Bien que l'origine et l'histoire évolutive, ainsi que la dynamique de transmission du virus de Lassa aient été révélées par des études épidémiologiques moléculaires récentes, les facteurs qui déterminent l'évolution du virus restent flous. Des modifications génétiques du génome viral pourraient avoir permis au virus de s'adapter à l'homme. Le diagnostic de la fièvre de Lassa est également passé des tests sérologiques de base à des méthodes plus sophistiquées telles que la réaction quantitative en chaîne par polymérase en temps réel (qRTPCR) et le séquençage, qui sont particulièrement utiles pour identifier les souches épidémiques. Plusieurs vaccins, y compris le virus recombinant de la stomatite vésiculeuse (rVSV), les particules pseudo-virales (VLP) et les vaccins à base d'ADN, se sont révélés prometteurs dans des modèles animaux et certains ont progressé vers des essais cliniques de phase 2. La prévention et le contrôle de la fièvre de Lassa sont essentiels pour préserver la santé et le bien-être des communautés touchées. Des mesures efficaces telles que le contrôle des rongeurs, l'amélioration de l'assainissement et la détection et l'isolement précoces des personnes infectées sont essentielles pour réduire la transmission. Des recherches continues sur les facteurs génétiques et écologiques qui déterminent l'évolution du virus de Lassa sont nécessaires pour réduire les impacts de la fièvre de Lassa.

Proceedings of the 2022 annual meeting of American Diabetes Association: Advances in diabetes mellitus and other metabolic diseases / 中华内分泌代谢杂志

The 82nd American Diabetes Association Academic Meeting was held in New Orleans, U. S.A. on June 3, 2022. The meeting had both in-person and virtual activities, encompassed the advances in diabetes study, prevention, and management, including the latest research results of Chinese researchers. This summary highlights the important research findings, including congress awards, drug research progress, management of complications/comorbidities, update of guideline/consensus, and progress of other metabolic diseases, with an aim to provide reference for diabetes management in China.

Latest advances in the diagnosis and treatment of interstitial cystitis/bladder pain syndrome / 现代泌尿外科杂志

Interstitial cystitis/bladder pain syndrome (IC/BPS) is characterized by pain, oppressing sensation, or discomfort associated with the bladder, accompanied by lower urinary tract symptoms, lasting for more than 6 weeks (or 6 months). Since IC/BPS was first reported, its diagnosis and treatment have been a challenge to clinicians. This article will review its classification and phenotype, fundamental research, imaging, symptom score, cystoscopy, treatment and potential therapeutic targets.

Comparison of active components in different parts of Perilla frutescens and its pharmacological effects / 中国中药杂志

Perilla frutescens is a widely used medicinal and edible plant with a rich chemical composition throughout its whole plant. The Chinese Pharmacopoeia categorizes P. frutescens leaves(Perillae Folium), seeds(Perillae Fructus), and stems(Perillae Caulis) as three distinct medicinal parts due to the differences in types and content of active components. Over 350 different bioactive compounds have been reported so far, including volatile oils, flavonoids, phenolic acids, triterpenes, sterols, and fatty acids. Due to the complexity of its chemical composition, P. frutescens exhibits diverse pharmacological effects, including antibacterial, anti-inflammatory, anti-allergic, antidepressant, and antitumor activities. While scholars have conducted a substantial amount of research on different parts of P. frutescens, including analysis of their chemical components and pharmacological mechanisms of action, there has yet to be a systematic comparison and summary of chemical components, pharmacological effects, and mechanisms of action. Therefore, this study overviewed the chemical composition and structures of Perillae Folium, Perillae Fructus, and Perillae Caulis, and summarized the pharmacological effects and mechanisms of P. frutescens to provide a reference for better development and utilization of this valuable plant.

Nuevos avances en cirugía hepática: evaluación y planificación preoperatoria (Parte 1) / New advances in liver surgery: evaluation and preoperative planning

Resumen Los avances en la cirugía hepática de los últimos años han permitido resecciones hepáticas más extensa y complejas para el tratamiento de diferentes patologías del hígado sin un aumento excesivo de la morbimortalidad perioperatoria. El desarrollo de diferentes técnicas, tecnologías y herramientas para la evaluación preoperatoria han mejorado la planificación quirúrgica con el uso por ejemplo de las tecnologías audiovisuales e impresión de modelos en 3 dimensiones (3D) de alta fidelidad. Otros avances, han permitido realizar una mejor evaluación funcional del parénquima hepático y una caracterización más precisa de las lesiones con el uso por ejemplo de verde de indocianina, cintigrafía hepática y resonancia magnética con contraste hepatoespecífico. Este artículo describe algunos de los nuevos avances en la evaluación y planificación preoperatoria en cirugía hepática.

Advances in liver surgery in recent years have made it possible to achieve more extensive and complex liver resections for the treatment of different liver diseases without an excessive increase in perioperative morbidity and mortality. The development of different techniques, technologies and tools for preoperative evaluation have improved surgical planning with the use, for example, of audiovisual technologies and printing of high-fidelity 3-dimensional (3D) models. Other advances have allowed a better functional evaluation of the liver parenchyma and a more precise characterization of the lesions with the use, for example of indocyanine green or liver scintigraphy and magnetic resonance with hepatospecific contrast. This article describes some of the new advances in preoperative evaluation and planning in liver surgery.

Análise do Impacto Orçamentário da Prevenção de Lesão por Pressão em Idosos Acamados / Analysis of the Budgetary Impact of Pressure Injury Prevention in Bedridden Elderly / Análisis del Impacto Presupuestario de la Prevención de Lesiones por Presión em Ancianos Encamados

Objetivo: Analisar o impacto orçamentário e o incremento de custos da incorporação de superfícies especiais para o manejo da pressão para prevenção de lesão por pressão em pacientes idosos acamados. Método: Análise de impacto orçamentário, seguindo as recomendações da diretriz metodológica análise de impacto orçamentário. Delinearam-se dois possíveis cenários (referência e alternativo 1, 2 e 3). Resultados: O custo em cinco anos no cenário de referência, adotando apenas a estratégia de mudança de decúbito, foi estimado em R$ 253.86,2542,81. Os custos nos cenários alternativos 1, 2 e 3 foram respectivamente, no mesmo período e com os ajustes econômicos, R$ 250.422.191,73, R$ 249.223.263,19 e R$ 248.029.130,37. Conclusão: A utilização de altas tecnologias nem sempre será o diferencial para o melhor desfecho clínico do paciente e poderá acarretar mais custo ao sistema.

Objective:To analyze the budgetary impact and the increase in costs of the incorporation of special surfaces for pressure management to prevent pressure injuries in bedridden elderly patients. Method: Budget impact analysis, following the recommendations of the budget impact analysis methodological guideline. Two possible scenarios were out lined. In the first (alternative) scenario, the elderly receives a prevention strategy that includes the use of a viscoelastic mattress as a pressure distribution surface and a change in position with a minimum interval of 2 hours. In the second scenario (reference), the elderly receives a prevention strategy that only includes a change in position with a minimum interval of 2 hours. All costs were estimated using the macro costing technique. Results: The results of the analysis of the budget impact speak in disfavor, therefore, contrary to the eventual incorporation of the viscoelastic mattress as a complementary strategy to the systematic change of decubitus, of at least every 2 hours as a measure to prevent pressure injuries. Conclusion: The use of high technologies will not always be the differential for the best clinical outcome of the patient and it can result in more cost to the system.

Objetivo:Analizar el impacto presupuestario y el incremento de costes de la incorporación de superfícies especiales para el manejo de la presión para la prevención de lesiones por presión em pacientes ancianos encamados. Método:Análisis de Impacto Presupuestario (AIO), siguiendo las recomendaciones de la Guía Metodológica de Análisis de Impacto Presupuestario. Se esbozaron dos escenarios posibles. Em el primer escenario (alternativo), las personas mayores recibe ecnologiategia de prevención que incluye el uso de um colchón viscoelástico ecnologiaficie de distribución de presiem y un cambio de poemión con un intervalo mínimo de 2 horas. Enel segundo escenario (referencia), los adultos mayore ecnologiana estrategia de prevención que solo incluye el cambio de posición conun intervalo mínimo de 2 horas. Todos los costos se estimaron utilizando la técnica de macro costos. Resultados: Los resultados del análisis de impacto presupuestario hablan desfavorablemente, por tanto, en contra de la eventual incorporación del colchón viscoe ecnologiamo estrategia complementaria al cambio sistemático de decúbito, de al menos cada 2 horas como medida de prevención de lesiones por presión. Conclusión: Se concluye que el ecnologiass tecnologías no siempre será el diferencial para el mejor desenlace clínico del paciente y que puede resultar em mayor costo para el sistema.

Neurocircuit models of obsessive-compulsive disorder: limitations and future directions for research

Obsessive-compulsive disorder (OCD) is a common psychiatric condition classically characterized by obsessions (recurrent, intrusive and unwanted thoughts) and compulsions (excessive, repetitive and ritualistic behaviors or mental acts). OCD is heterogeneous in its clinical presentation and not all patients respond to first-line treatments. Several neurocircuit models of OCD have been proposed with the aim of providing a better understanding of the neural and cognitive mechanisms involved in the disorder. These models use advances in neuroscience and findings from neuropsychological and neuroimaging studies to suggest links between clinical profiles that reflect the symptoms and experiences of patients and dysfunctions in specific neurocircuits. Several models propose that treatments for OCD could be improved if directed to specific neurocircuit dysfunctions, thereby restoring efficient neurocognitive function and ameliorating the symptomatology of each associated clinical profile. Yet, there are several important limitations to neurocircuit models of OCD. The purpose of the current review is to highlight some of these limitations, including issues related to the complexity of brain and cognitive function, the clinical presentation and course of OCD, etiological factors, and treatment methods proposed by the models. We also provide suggestions for future research to advance neurocircuit models of OCD and facilitate translation to clinical application.

Nuevo algoritmo de test genéticos para evaluación de trastornos del neurodesarrollo / New genetic testing algorithm for evaluation of neurodevelopmental disorders

Resumen En más de la mitad de los trastornos del neurodesarrollo se demuestra una etiología genética. La detección de estas variantes patogénicas tiene un impacto enorme en el curso de la enfermedad de estos pacientes. Permite la aceptación de la enfermedad por parte de los padres de los pacientes, emitir un pronóstico, adelantarnos a las futuras consecuencias de la enfermedad y, en cada vez más casos, instaurar un tratamiento o cambiar el ya establecido. Las técnicas genéticas que permiten estos diagnósticos etiológicos son muy jóvenes y por lo tanto todavía no totalmente asumidas por los neuropediatras. Incluso en las guías de diag nóstico de las diferentes sociedades científicas, sus algoritmos están desfasados por la rápida incorporación de nuevas técnicas. En este artículo se revisan las técnicas actuales así como los últimos avances en las mismas, que se están incorporando a la práctica clínica.

Abstract In more than half of neurodevelopmental disorders, a genetic etiology is demonstrated. The detection of these pathogenic variants has a huge impact on the course of the disease of these patients. It allows the acceptance of the disease by the parents of the patients, issue a prognosis, anticipate the future consequences of the disease and in more and more cases establish a treatment or change the one already established. The genetic techniques that allow these etiological diagnoses are very recent therefore not yet fully assumed by neuropediatricians. Even in the diagnostic guides of the different scientific societies, their algorithms are outdated by the quick incorpora tion of new techniques. This article reviews the current techniques as well as the latest advances in them that are being incorporated into clinical practice.

New development of lipid-lowering therapy of coronary heart disease: Inclisiran / 中国临床药理学与治疗学

Because of high rate of nonadherence to statins, the subcutaneously injection of Inclisiran therapy intervals are from 3 months to 6 months, which will increase the patients' adherence to the Inclisiran therapy. In this review, we summarize the latest advances of Inclisiran, and review the phase 2 and phase 3 clinical trials results, adverse events, and the clinical trials results in progress of Inclisiran. Finally, we discuss the current status of Inclisiran in the clinical works.

New development of lipid-lowering therapy of coronary heart disease: Evinacumab / 中国临床药理学与治疗学

Homozygous familial hypercholesterolemia is a rare genetic disorder of lipid metabolism, traditional lipid-lowering therapies such as statins and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have little efficacy in these patients. Evinacumab can reduce the levels of LDL-C effectively. In this review, we summarize the latest advances in Evinacumab, and review the phase 2 and phase 3 clinical trials results, adverse events, and the clinical trials results in progress of Evinacumab. Finally, we discuss the current status of Evinacumab in the clinical works.

Research advances in the role of gastrointestinal microbe in pancreatic cancer / 中华肝胆外科杂志

In recent years, there have been increasing studies on the role of microorganisms in pancreatic cancer which show that bacteria and fungi are closely associated with pancreatic cancer. In the past, the pancreas has usually been considered as a sterile organ. Recent studies, however, show that microbiome exists in the pancreas. Bacteria can migrate from the intestine to the pancreas. Changing the composition of the microbiome may have positive effects on treatment of pancreatic cancer. This article reviews the relationship between gastrointestinal microbiome and pancreatic cancer.

Recent advances in multidisciplinary therapy for sinonasal cancers / 中华放射肿瘤学杂志

Sinonasal cancers (SNCs) are rare and heterogeneous diseases. Most patients present with locally advanced stage due to the insidious symptoms. In the majority of cases, the treatment strategy relies on the combination of surgery and radiotherapy, supplemented with or without chemotherapy. However, postoperative organ preserving rate is low, quality of life and clinical prognosis are poor. With recent advancement of surgical techniques, radiotherapy and chemotherapy techniques, certain progress has been reached in the diagnosis and treatment of SNCs. Nevertheless, the specific treatment regimen remains controversial. In this article, advances and controversies in SNC were reviewed.

Research progress in biological markers of perinatal depression / 中国药科大学学报

@#Perinatal depression, one of the most common complications in the perinatal period, has a significant impact on the physical and mental health of mothers and children.At present, it is difficult to diagnose perinatal depression at an early stage, so objective and effective biomarkers are of great significance for the early detection and treatment of perinatal depression. In recent years, the exploration of biomarkers for early diagnosis of perinatal depression has become a hot research topic, mainly in sex hormones, neuroendocrine-related hormones, immuno-inflammatory molecules, genetics, and epigenetics.This article reviews the research progress of the biomarkers of perinatal depression in recent years.